OLN241220P35000
- 0.10
- 0.000.00%
Olin Newsroom
Olin Bio (688319.SH): received government subsidies of 2.24 million yuan.
On November 28, Gelonghui reported that olin biology (688319.SH) announced that its wholly-owned subsidiary Chongqing Yuanlun Biological Technology Co., Ltd. recently received government subsidies totaling 2.24 million yuan, of which 2.24 million yuan is related to income and 0 yuan is related to assets.
When Should You Buy Olin Corporation (NYSE:OLN)?
Are Options Traders Betting on a Big Move in Olin (OLN) Stock?
Olin Announces Leadership Transition With New CLO Appointment
Olin's New Receivables Purchase Agreement and Financial Shift
Express News | Olin Corp - Agreement Has Three-Year Term
Express News | Olin Corp - Enters Into $500 Million Receivables Purchase Agreement
US Manufacturing Index Rises To 43, Highest Since 2020
Olin To Go Ex-Dividend On November 14th, 2024 With 0.2 USD Dividend Per Share
November 12th (Eastern Time) - $Olin(OLN.US)$ is trading ex-dividend on November 14th, 2024.Shareholders of record on November 14th, 2024 will receive 0.2 USD dividend per share on December 13th, 2024
Olin Corporation (NYSE:OLN) Will Pay A US$0.20 Dividend In Three Days
FBI Firearm Background Checks Track Higher Ahead of the U.S. Election
Piper Sandler Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $51
Olin Is Maintained at Market Perform by BMO Capital
Olin Biology (688319.SH): The proposed additional fundraising will not exceed 0.3 billion yuan.
On October 29, Gelonhui announced that Olin Biotech (688319.SH) disclosed that the total amount of funds raised by the company in this issuance of stocks shall not exceed 175.2929 million yuan (including this amount), not more than 0.3 billion yuan and not more than 20% of the net assets at the end of the most recent year. The net proceeds from the funds raised after deducting the relevant issuance expenses are intended to be invested in the following project: the technical renovation project of the vaccine R&D production base.
Morgan Stanley Maintains Olin(OLN.US) With Sell Rating, Maintains Target Price $41
Express News | Olin Corp : BMO Cuts Target Price to $47 From $50
RBC Capital Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $48
Olin Biosciences (688319.SH): The net income in the first three quarters was 4.0259 million yuan, a year-on-year decrease of 86.71%.
Gelonghui October 29th news｜Olin Biology (688319.SH) announced the third quarter report of 2024, the company's revenue for the first three quarters of the year was 0.387 billion yuan, a year-on-year increase of 9.75%; net income attributable to shareholders of listed companies was 4.0259 million yuan, a year-on-year decrease of 86.71%; basic earnings per share were 0.0099 yuan.
Evaluating Olin: Insights From 6 Financial Analysts
Olin Analysts Slash Their Forecasts After Q3 Earnings